{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "exchange": "FRA", "shortName": "ORYZON GENOMICS SA EO-,05", "longName": "Oryzon Genomics S.A.", "messageBoardId": "finmb_2985449", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChangePercent": -1.9512177, "regularMarketPrice": 2.01, "marketState": "REGULAR", "firstTradeDateMilliseconds": 1522994400000, "priceHint": 4, "epsTrailingTwelveMonths": -0.07, "sharesOutstanding": 57581900, "bookValue": 1.313, "fiftyDayAverage": 2.1825, "fiftyDayAverageChange": -0.1724999, "fiftyDayAverageChangePercent": -0.079037756, "twoHundredDayAverage": 2.306525, "twoHundredDayAverageChange": -0.296525, "twoHundredDayAverageChangePercent": -0.1285592, "marketCap": 119127072, "priceToBook": 1.5308454, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "regularMarketChange": -0.03999996, "regularMarketTime": 1683872766, "regularMarketDayHigh": 2.01, "regularMarketDayRange": "2.01 - 2.01", "regularMarketDayLow": 2.01, "regularMarketVolume": 193, "regularMarketPreviousClose": 2.05, "bid": 2.065, "ask": 2.07, "bidSize": 0, "askSize": 0, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 2.01, "averageDailyVolume3Month": 26, "averageDailyVolume10Day": 21, "fiftyTwoWeekLowChange": 0.004999876, "fiftyTwoWeekLowChangePercent": 0.0024937035, "fiftyTwoWeekRange": "2.005 - 2.975", "fiftyTwoWeekHighChange": -0.9649999, "fiftyTwoWeekHighChangePercent": -0.32436973, "fiftyTwoWeekLow": 2.005, "fiftyTwoWeekHigh": 2.975, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "symbol": "ORN.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Sant Ferran 74", "city": "Cornell\u00e0 de Llobregat", "zip": "08940", "country": "Spain", "phone": "34 93 515 13 13", "fax": "34 93 377 40 28", "website": "https://www.oryzon.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornell\u00e0 de Llobregat, Spain.", "fullTimeEmployees": 43, "companyOfficers": [{"maxAge": 1, "name": "Dr. Carlos Manuel Buesa  Arjol", "title": "Co-Founder, Chairman, CEO & Pres", "fiscalYear": 2015, "totalPay": {"raw": 58000, "fmt": "58k", "longFmt": "58,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Enric Rello Condomines", "title": "Director of Operations, COO & CFO", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jordi Xaus Pey", "title": "Chief Scientific Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Xavier Perpinya Ribera", "title": "Head of Internal Audit & Compliance", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Emili Torrell Cortada", "title": "Chief Bus. Devel. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Neus Virgili Bernado", "title": "Chief Intellectual Property Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Michael Thomas Ropacki Ph.D.", "title": "Chief Medical Officer of CNS", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Sonia Paloma Gutierrez Bezon", "title": "Chief of Clinical Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Saikat  Nandi", "title": "Global Chief Bus. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Ana  Limon", "title": "Sr. VP of Clinical Devel. & Global Medical Affairs", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1451520000, "maxAge": 86400}}], "error": null}}